- Home
- GNLX vs NVNO Comparison
GNLX vs NVNO Comparison
Compare GNLX & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- NVNO
- Stock Information
- Founded
- GNLX 2001
- NVNO 1987
- Country
- GNLX United States
- NVNO United States
- Employees
- GNLX N/A
- NVNO N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- NVNO Medical/Dental Instruments
- Sector
- GNLX Health Care
- NVNO Health Care
- Exchange
- GNLX Nasdaq
- NVNO Nasdaq
- Market Cap
- GNLX 96.6M
- NVNO 78.7M
- IPO Year
- GNLX 2023
- NVNO N/A
- Fundamental
- Price
- GNLX $2.83
- NVNO $4.05
- Analyst Decision
- GNLX Strong Buy
- NVNO
- Analyst Count
- GNLX 4
- NVNO 0
- Target Price
- GNLX $17.75
- NVNO N/A
- AVG Volume (30 Days)
- GNLX 157.9K
- NVNO 135.7K
- Earning Date
- GNLX 08-13-2025
- NVNO 07-30-2025
- Dividend Yield
- GNLX N/A
- NVNO N/A
- EPS Growth
- GNLX N/A
- NVNO N/A
- EPS
- GNLX N/A
- NVNO N/A
- Revenue
- GNLX N/A
- NVNO N/A
- Revenue This Year
- GNLX N/A
- NVNO N/A
- Revenue Next Year
- GNLX N/A
- NVNO $409.09
- P/E Ratio
- GNLX N/A
- NVNO N/A
- Revenue Growth
- GNLX N/A
- NVNO N/A
- 52 Week Low
- GNLX $1.60
- NVNO $2.03
- 52 Week High
- GNLX $5.89
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- GNLX 57.73
- NVNO 54.46
- Support Level
- GNLX $2.85
- NVNO $4.19
- Resistance Level
- GNLX $3.29
- NVNO $4.52
- Average True Range (ATR)
- GNLX 0.22
- NVNO 0.39
- MACD
- GNLX 0.06
- NVNO -0.01
- Stochastic Oscillator
- GNLX 64.74
- NVNO 47.29
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.